<DOC>
	<DOCNO>NCT02427373</DOCNO>
	<brief_summary>A multiple-dose , double-blind , randomize , four-week , three-treatment , parallel study 66 healthy adult subject receive 6 capsules/d , administer dose 1.3 g/d eicosapentaenoic acid ( EPA ) +docosahexaenoic acid ( DHA ) fish oil ethyl ester ( EE ) , fish oil triglyceride ( TG ) krill oil total 4 week . The objective study compare oral bioavailability EPA+DHA total plasma across three formulation end 4 week study .</brief_summary>
	<brief_title>A Parallel Bioavailability Study Fish Oil-Ethyl Ester Versus Fish Oil-Triglyceride Versus Krill Oil</brief_title>
	<detailed_description />
	<criteria>Healthy , adult female neither pregnant breastfeeding , healthy , adult male body mass index ( BMI ) 18 30 kg/m2 ( inclusive ) , minimum weight 50 kg ( 110 lb ) . history presence diabetes , high triglyceride ( ≥240 mg/dL ) , high cholesterol ( ≥240 mg/dL ) ; clinically significant abnormal find physical exam , medical history , vital sign , clinical laboratory result screen ; history presence allergic response omega3fatty acid sensitivity allergy fish shellfish ; history coagulation disorder current anticoagulation therapy ; use nutritional supplement , omega3 supplement , fish oil , chia , krill oil , flaxseed food supplement omega3s within 3 month prior first dose study medication ; use prescription medication , except hormonal contraceptive hormonal replacement therapy , within 14 day prior first dose study medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>bioavailability</keyword>
	<keyword>fish oil</keyword>
	<keyword>krill oil</keyword>
</DOC>